Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to certain thiazolopyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and 5 their use in therapy.
• Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
• These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif.
• the chemokine superfamily comprises three ⁇ 5 groups exhibiting characteristic structural motifs, the C-X-C, C-C and C-X3-C families.
• the C-X-C and C-C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues.
• the C-X3-C family is distinguished from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine
• the C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
• IL-8 interleukin-8
• NAP-2 neutrophil-activating peptide 2
• the C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins l ⁇ and l ⁇ (MlP-l ⁇ and MlP-l ⁇ ).
• the C-X3-C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.
• chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCRl 1 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX3CRI for the C-X3-C family.
• These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.
• R represents a hydrogen atom, or a group -NR 4 R 5 ;
• R 4 and R 5 each independently represent a hydrogen atom, or a 4-piperidinyl, C 3 -C 6 cycloalkyl or C,-C 8 alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR 6 R 7 , - CONR 6 R 7 , -OR 8 , -COOR 8 , -NR 9 COR 10 , -SR 1 1 , -SO 2 R ⁇ , -SO 2 NR 6 R 7 , -NR 9 SO 2 R 10 , morpholinyl, C ⁇ -C alkyl, C 3 -C 6 cycloalkyl, tetrahydrofuranyl, aryl and heteroaryl groups, the aryl and heteroaryl groups being optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR 6 R 7 , - CONR 6 R 7 , -OR
• R 1 represents a C ⁇ -C 8 alkyl group optionally containing one or more atoms independently selected from O, NR or S which terminates in a heteroaryl group, the latter group may be optionally substituted by one or more substituent groups independently selected from halogen atoms, -NR 6 R 7 , -CONR 6 R 7 , -OR 8 , -COOR 8 , -NR 9 COR 10 , -SR 11 , -SO 2 R n , - SO 2 NR 6 R 7 , -NR 9 SO 2 R 10 , C ⁇ -C 6 alkyl, trifluoromethyl, or an aryl or heteroaryl group each of
• R 2 and R 3 each independently represent a hydrogen atom, or a C 3 -C 7 carbocyclic, C ⁇ -C 8 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl group, the latter four groups may be optionally substituted by one or more substituent groups independently selected from: halogen atoms , -NR 6 R 7 , -CONR 6 R 7 , -OR 8 , -COOR 8 , -NR 9 COR 10 , -SR 11 , -SO 2 R ⁇ , - SO 2 NR 6 R 7 , -NR 9 SO 2 R 10 or a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR 9 and itself optionally substituted by C 1- -alkyl, halogen,
• R 8 represents hydrogen, C ⁇ -C 6 alkyl or a phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR 14 and -NR 15 R 16 , -CONR 15 R 16 , -NR 15 COR 16 , -SO 2 NR 15 R 16 , NR 15 SO 2 R 16
• R 6 and R 7 independently represent a hydrogen atom or a C ⁇ -C 6 alkyl or phenyl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR 14 and -NR 15 R 16 , -CONR 15 R 16 , -NR 15 COR 16 , -SO 2 NR 15 R 16 , NR 15 SO 2 R 16 or
• R 6 and R 7 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally comprising a further heteroatom selected from oxygen and nitrogen atoms, which ring system may be optionally substituted by one or more substituent groups independently selected from phenyl, -OR 14 , -COOR 14 , -NR 15 R 16 , -CONR 15 R 16 , -NR 15 COR 16 , -SO 2 NR 15 R 16 , NR 15 SO 2 R 16 or C C 6 alkyl, itself optionally substituted by one or more substituents independently selected from halogen atoms and -NR 15 R 16 and -OR 17 groups, R 11 represents a hydrogen atom or a C ⁇ -C 6 , or phenyl group, each of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, phenyl, -OR 17 and -NR 15 R 16 , and
• R 9 , R 10 , R 12 , R 13 , R 14 R 15 , R 16 , and R 17 independently represent a hydrogen atom or a C ⁇ -C 6 , alkyl, or a phenyl group.
• an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched.
• Aryl groups include phenyl and naphthyl.
• Heteroaryl is defined as a 5- or 6-membered aromatic ring optionally containing one or more heteroatoms selected from N, S, O. Examples include pyridine, pyrimidine, thiazole, oxazole, pyrazole, imidazole, furan.
• Heterocyclic rings as defined for R 4 and R 5 means satin atcd hctcrocyclcs, examples of which include morphohnc, a ctidmc, py ⁇ olidinc. pipc ⁇ dinc and pipci a/inc
• the group R represents a hydrogen atom, or a group -NR R .
• R 4 and R 5 each independently represent a hydrogen atom, or a 4-piperidinyl, C 3 - C 6 cycloalkyl or C ⁇ -C 8 alkyl group, which latter two groups may be optionally substituted by one or more substituent groups independently selected from halogen atoms and -NR 6 R 7 , -CONR 6 R 7 , -OR 8 , -COOR 8 , -NR 9 COR 10 , -SR 1 1 , -SO 2 R n , -SO 2 NR 6 R 7 , -NR y SO 2 R 10 , morpholinyl, C ⁇ -C alkyl, C 3 -C 6 cycloalkyl, tetrahydrofuranyl, aryl and heteroaryl groups, each of which may be optionally substituted by one or more substituents independently selected from halogen atoms and cyano, nitro, -NR 6 R 7 , -CONR 6 R 7 , -OR 8
• Particularly advantageous compounds of formula (I) are those in which R and R each represent a hydrogen atom.
• R 1 represents a C,-C 8 alkyl group optionally containing one or more atoms independently selected from O, NR 6 or S which terminates in a heteroaryl group, the latter group may be optionally substituted by one or more substituent groups independently selected from halogen atoms, -NR 6 R 7 , -CONR 6 R 7 , -OR 8 , -COOR 8 , -NR 9 COR 10 , -SR 11 , -SO 2 R ⁇ , -SO 2 NR 6 R 7 , -NR 9 SO 2 R 10 , C,-C 6 alkyl, trifluoromethyl, or an aryl or heteroaryl group each of which can be optionally substituted by one or more substituents independently selected from halogen atoms, cyano, nitro, -NR 6 R 7 , -CONR 6 R 7 , -OR 8 , -COOR 8 , -NR 9 COR 10 , -SR 11 , -SO
• Particularly advantageous compounds of formula (I) are those in which R represents a methyl group substituted by a five-membered heterocycle such as furan or thiazole.
• R and R each independently represent a hydrogen atom, or a C -C carbocyclic, C ⁇ -C 8 alkyl, C 2 -C 6 alkenyl or C -C 6 alkynyl group, the latter four groups may be optionally substituted by one or more substituent groups independently selected from: halogen atoms , -NR 6 R 7 , -CONR 6 R 7 , -OR 8 , -COOR 8 , -NR 9 COR 10 , -SR 1 1 , -SO 2 R ⁇ , - SO 2 NR 6 R 7 , -NR 9 SO 2 R 10 or a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR 9 and itself optionally substituted by C ⁇ -3 -alkyl, halogen.
• substituent groups independently selected from: halogen atoms , -NR 6 R 7 , -CONR 6 R 7 , -OR 8 , -COOR 8
• R 2 and R 3 is hydrogen and the other is C ⁇ -C 8 alkyl substituted by hydroxy and one or more methyl or ethyl groups. More preferably one of R and R is hydrogen and the other is CH(CH 3 )CH 2 OH, CH(Et)CH 2 OH, C(CH 3 ) 2 CH 2 OH or CH(CH 2 OH) 2 .
• R 2 and R 3 is hydrogen and the other is CH(CH 3 )CH 2 OH or CH(Et)CH 2 OH the resulting compounds of formula (I) are preferably in the form of the (R) isomer. Most preferably one of R 2 and R 3 is hydrogen and the other is CH(CH )CH 2 OH.
• Particularly preferred compounds of the invention include:
• R, R , R and R are as defined in formula (I) or are protected derivatives thereof with a thiol R'SH in the presence of a base, or
• R, R and R are as defined in formula (I) or are protected derivatives thereof with a compound of formula R'X where R 1 is as defined in formula (I) and X is a leaving group, and optionally after (a) or (b):
• Reaction (a) may be carried out in a solvent such as DMSO at a temperature between 0°C and 100°C using a base such as potassium tert-butoxide.
• Reaction (b) may be carried out in NMP at room temperature.
• the leaving group X is preferably halogen such as bromide.
• the reaction is carried out in the presence of a base such as N,N-diisopropylethylamine.
• the reaction may be carried out in a suitable solvent such as ⁇ MP at room temperature.
• R, R 1 , R and R 3 are as defined above with an oxidizing agent such as peracetic acid.
• the reaction may be carried out in a solvent such as glacial acetic acid at a temperature between 0°C and 100°C.
• Compounds of formula (IV) where R, R 1 , R 2 and R 3 are as defined in formula (I) may be prepared by treatment of a compound of formula (V) where R and R 1 is as defined above and L is a halogen such as chlorine with an amine H ⁇ R 2 R .
• the reaction may be carried out in a solvent such as tetrahydrofuran in a sealed vessel at a temperature between 0°C and 150°C.
• Compounds of formula (V) where R and R 1 are as defined in formula (I) and L is a halogen may be prepared by treating a compound of formula (V) where R and R 1 are as defined in formula (I) and L is a hydroxyl group with a halogenating agent such as phosphorous oxychloride. The reaction may be carried out at reflux in the presence of dimethylaniline.
• Compounds of formula (V) where R and R 1 is defined in formula (I) and L is a halogen can be prepared from compounds of formula (V) where R is a halogen and R 1 is defined above with an amine NR )4 R ⁇ > 5.
• the reaction may be carried out in a solvent such as tetrahydrofuran in a sealed vessel at a temperature between 0°C and 150°C.
• R 1 is as defined above and X is a leaving group such as bromide in the presence of a base such as sodium hydroxide.
• Novel intermediate compounds form a further aspect of the invention.
• compounds of formula (II) and (III) are novel and form an aspect of the invention.
• the compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or/?-toluenesulphonate.
• a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine
• an acid addition salt such as a hydrochloride, hydrobromide, phosphat
• the compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines.
• modulators of chemokine receptor especially CXCR2
• CXCR2 chemokine receptor 2
• Examples of such conditions/diseases include:
• obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
• COPD chronic obstructive
• Neurodegenerative diseases and dementia disorders e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt- Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g.
• multiple sclerosis multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis
• neuromuscular disorders e.g. myasthenia gravis and Lambert- Eaton syndrome
• spinal diorders e.g. tropical spastic paraparesis
• stiff-man syndrome paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis
• CNS trauma migraine
• migraine migraine
• NSCLC non-small cell lung cancer
• malignant melanoma malignant melanoma
• prostate cancer squamous sarcoma
• tumour metastasis tumour metastasis
• Reproductive Diseases e.g. Disorders of ovulation, menstruation and implantation, Pre-term labour, Endometriosis
• the present invention provides a compound of formula (I), or a pharmaceutically- acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
• the compounds of the invention are used to treat diseases in which the chemokine receptor belongs to the CXC chemokine receptor subfamily, more preferably the target chemokine receptor is the CXCR2 receptor,
• diseases in which the chemokine receptor belongs to the CXC chemokine receptor subfamily more preferably the target chemokine receptor is the CXCR2 receptor
• Particular conditions which can be treated with the compounds of the invention are psoriasis, diseases in which angiogenesis is associated with raised CXCR2 chemokine levels, and COPD. It is preferred that the compounds of the invention are used to treat psoriasis.
• certain compounds of formula (I) may have utility as antagonists of the CX3CR1 receptor.
• Such compounds are expected to be particularly useful in the treatment of disorders within the central and peripheral nervous system and other conditions characterized by an activation of microglia and/or infiltration of leukocytes (e.g. stroke/ischemia and head trauma).
• the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
• the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.
• the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
• the terms “therapeutic” and “therapeutically” should be construed accordingly.
• the invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CXCR2) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
• a chemokine especially CXCR2
• the invention also provides a method of treating an inflammatory disease, especially psoriasis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
• a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined.
• the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
• the compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
• the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
• the present invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
• the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
• compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
• the compounds of the invention are administered orally.
• FC024 fraction collector or a Waters Delta Prep 4000.
• the abbreviations m.p. and DMSO used in the examples stand for melting point and dimethyl sulphoxide respectively.
• 6-Amino-2-[(phenylmethyl)thio]-4(lH)-pyrimidinone (10.5g)[ preparation as described in WO 9635678] and potassium thiocyanate (25g) in N,N-dimethylformamide (200ml) were heated together at 65°C. Pyridine (6.3ml) was added and the solution cooled to 5°C. Bromine (2.2ml) was added slowly and the reaction mixture stirred for 2 hours at 5-10°C. The reaction mixture was poured onto ice water, stirred for 1 hour and the solid was isolated by filtration. After washing with water and ether, a pure sample was obtained after tituration with hot methanol.
• step a) The product of step a) (7.35g) was heated at 120°C in NN-dimethylformamide (40ml)/water (10ml) for 10 hours. After cooling, the resulting solid was filtered off, washed with water, then ethyl acetate to give the subtitle compound.
• step (b) The product from step (b) (0.89g), phosphorus oxychloride (12ml) and NN- dimethylaniline (1.2ml) were heated at reflux for 2 hours. The cooled reaction mixture was poured onto ice water and stirred for 2 hours. Chromatography (SiO 2 , methanol/dichloromethane as eluant) gave the sub-title compound.
• step (c) The product from step (c) (0.6g) and 2-amino-2-methylpropanol (l. lg) in tetrahydrofuran (10ml) was heated in a sealed vessel at 100 °C for 18 hours. The mixture was evaporated to dryness and purified (SiO 2 , ethyl acetate as eluant) to give the subtitle compound (0.46g).
• step (e) The product from step (e) was taken up in DMSO (7.5ml) and treated with potassium t- butoxide (IM in THF, 4.95ml). An aliquot of the solution (1ml) was treated with (1H- benzimidazol-2-yl)methanethiol (0.063g) and stirred at 50°C for 1 hour. The solution was treated with glacial acetic aci J (1ml) and purified by reverse phase preparative HPLC on Symmetry ® C8 column, using 10 to 60% acetonitrile in 0.1% aqueous ammonium acetate at 20ml/min over 5 min to give the titled compound (0.013g)
• the titled compound was prepared from furfuryl mercaptan (0.043g) using the method of example 1, step (f) (0.013g)
• ⁇ ⁇ NNMMRR : ⁇ ((DDMMSSOO)) 1I.M33 (s, 6H), 3.55 (d, 2H), 4.38 (s, 2H), 4.87 (t, IH), 6.30-6.38 (m,
• the titled compound was prepared from l-(2-thienyl)ethyl mercaptan (0.055g) using the method of example 1, step (f) (0.008g)
• step (a) A stirred solution of the product of step (a) (lg) in liquid ammonia (20ml) was treated portionwise with sodium until a permanent blue colour was obtained. The solution was treated with ammonium chloride to dissipate the blue colour, and allowed to evaporate, The residue was taken up in water, filtered and purified by reverse phase preparative
• step (b) A stirred solution of the product of step (b) (0.05g) in DMSO (4ml) was treated with a solution of 4-chloromethyl-2-methylthiazole hydrochloride (0.029g) and Hunig's base (0.025g) in NMP (0.5ml) and stirred for 1 hour.
• the solution was purified by reverse phase preparative HPLC on Nova-pak ® C18 column, using 10 to 60% acetonitrile in 0.1% aqueous ammonium acetate at 50ml/min over 10 min to give the titled compound (0.02 lg)
• ⁇ 'H NNMMRR : ⁇ ((CCDD 33 OODD)) 1l..21 (d, 3H), 2.68 (s, 3H), 3.48-3.64 (mult., 2H), 4.33-4.40 (mult., lH), 4.46 (s, 2H), 7.31 (s,lH)
• the titled compound was prepared from the product of example 4, step (b), and 3,5- dimethyl-4-chloromethylisoxazole using the method of example 4, step (c) to give a white powder (0.016g)
• step (e) The product from example 4, step (a), was converted into the subtitled compound by the method of example 1 , step (e)
• step (a) A solution of the product from step (a) was converted into the titled compound using the product from step (b), and the method of example 1, step (f)
• the titled compound was prepared from the product of example 4, step (b), and ⁇ -[4- (chloromethyl)-2-thiazolyl]-acetamide, using the method of example 4, step (c)
• the titled compound was prepared from the product of example 4, step (b), and 5-chloro- 4-(chloromethyl)-l,2,3-thiadiazole, using the method of example 4, step (c).
• the titled compound was prepared from the product of example 4, step (b), and 5- bromomethylisoxazole, using the method of example 4, step (c).
• step (a) The product from step (a) (24.3g) was stirred in dry DMF (400ml) with pyridine (13.1ml) and potassium thiocyanate (37. lg) at 0C. Bromine (4.5ml) was added overlhr and the mixture kept at 0C for a further 2hrs. The mixture was poured onto water to give a solution which was then evaporated to low volume. Water was added to give a precipitate which was collected. The solid was dissolved in dilute hydrochloric acid and reprecipitated by the addition of sodium bicarbonate solution. The solid was collected, washed with water and dried to afford the sub-title compound (8.7g)
• step (b) The product from step (b), (8.7g), was suspended in phosphorus oxychloride (88ml) and dimethylaniline (8.8ml). The mixture was heated under reflux for 2hrs then evaporated. The residue was stirred in hot water, cooled and the pH adjusted with sodium hydroxide solution to pH5. The solid was collected, washed with water and dried. Chromatography (SiO 2 , methanol/dichloromethane as eluant) gave the sub-title compound (4.3g)
• step (c) The product from step (c) (0.99g) and 2-amino-l,3-propanediol (0.55g), were stirred in dry NMP (10ml) with hunigs base (1.75ml) at 100C for 20hrs. The mixture was poured onto water and evaporated. Water was added and the solid collected, washed with water and dried. A sample (0.1 lg) was purified by reverse phase preparative HPLC on Nova-pak ® C18 column, using acetonitrile in 0.1% aqueous ammonium acetate gave the titled compound (0.04g) Mp 158-160C MS: APCI+ve 385 (M+H, 100%)
• the titled compound was prepared from the product of example 1, step (e) and furfuryl mercaptan (0.15ul) using the method of example 1, step (f) (0.024g)
• [ I]IL-8 (human, recombinant) was purchased from Amersham, U.K. with a specific activity of 2,000Ci/mmol. All other chemicals were of analytical grade. High levels of hrCXCR2 were expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No. 85120602) (Lee et al. fl992J J. Biol. Chem. 267 ppl6283-16291). hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA. The DNA was cloned into PCRScript (Stratagene) and clones were identified using DNA.
• the coding sequence was sub-cloned into the eukaryotic expression vector RcCMV (Invitrogen). Plasmid DNA was prepared using Quiagen Megaprep 2500 and transfected into HEK 293 cells using Lipofectamine reagent (Gibco BRL). Cells of the highest expressing clone were harvested in phosphate-buffered saline containing 0.2%(w/v) ethylenediaminetetraacetic acid (EDTA) and centrifuged (200g, 5min.).
• EDTA ethylenediaminetetraacetic acid
• the cell pellet was resuspended in ice cold homogenisation buffer [lOmM HEPES (pH 7.4), lmM dithiothreitol, lmM EDTA and a panel of protease inhibitors (ImM phenyl methyl sulphonyl fluoride, 2 ⁇ g/ml soybean trypsin inhibitor, 3mM benzamidine, 0.5 ⁇ g/ml leupeptin and lOO ⁇ g/ml bacitracin)] and the cells left to swell for 10 minutes.
• the cell preparation was disrupted using a hand held glass mortar/PTFE pestle homogeniser and cell membranes harvested by centrifugation (45 minutes, 100,000g, 4°C).
• the membrane preparation was stored at -70°C in homogenisation buffer supplemented with Tyrode's salt solution (137mM NaCl, 2.7mM KC1, 0.4mM NaH 2 PO 4 ), 0.1%(w/v) gelatin and 10%(v/v) glycerol.
• the assay was initiated with the addition of membranes and after 1.5 hours at room temperature the membranes were harvested by filtration using a Millipore MultiScreen vacuum manifold and washed twice with assay buffer (without bacitracin). The backing plate was removed from the
• MultiScreen plate assembly the filters dried at room temperature, punched out and then counted on a Cobra ⁇ -counter.
• Human neutrophils were prepared from EDTA-treated peripheral blood, as previously described (Baly et al. (1997) Methods in Enzymology 287 pp70-72), in storage buffer [Tyrode's salt solution (137mM NaCl, 2.7mM KC1, 0.4mM NaH 2 PO 4 ) supplemented with 5.7mM glucose and lOmM HEPES (pH 7.4)].
• chemokine GRO ⁇ human, recombinant
• R&D Systems Abingdon, U.K.
• All other chemicals were of analytical grade. Changes in intracellular free calcium were measured fluorometrically by loading neutrophils with the calcium sensitive fluorescent dye, fluo-3, as described previously (Merritt et al. (1990) Biochem. J. 269, pp513-519).
• FLIPR Fluorometric Imaging Plate Reader

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9885290

Family Applications (1)

Country Status (8)

Cited By (9)

Families Citing this family (8)

Citations (6)

Family Cites Families (49)

• 2000
  • 2000-02-11 GB GB0003025A patent/GB2359081A/en not_active Withdrawn
• 2001
  • 2001-02-07 EP EP01906447A patent/EP1257556B1/en not_active Expired - Lifetime
  • 2001-02-07 US US10/203,580 patent/US6958343B2/en not_active Expired - Fee Related
  • 2001-02-07 JP JP2001558056A patent/JP2003522192A/ja active Pending
  • 2001-02-07 WO PCT/SE2001/000247 patent/WO2001058907A1/en not_active Ceased
  • 2001-02-07 AT AT01906447T patent/ATE269340T1/de not_active IP Right Cessation
  • 2001-02-07 AU AU2001234273A patent/AU2001234273A1/en not_active Abandoned
  • 2001-02-07 DE DE60103856T patent/DE60103856T2/de not_active Expired - Fee Related

Patent Citations (6)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events